Literature DB >> 21053303

Measurement of myeloid cell immune suppressive activity.

Luigi Dolcetti1, Elisa Peranzoni, Vincenzo Bronte.   

Abstract

This unit presents simple methods to assess the immunosuppressive properties of immunoregulatory cells of myeloid origin, such as myeloid-derived suppressor cells (MDSCs), both in vitro and in vivo. These methods are general and could be adapted to test the impact of different suppressive populations on T cell activation, proliferation, and cytotoxic activity; moreover they could be useful to assess the influence exerted on immune suppressive pathways by genetic modifications, chemical inhibitors, and drugs.

Mesh：

Year:  2010        PMID： 21053303     DOI： 10.1002/0471142735.im1417s91

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN： 1934-3671


  10 in total

Review 1.  Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications.

Authors:  C Marcela Diaz-Montero; Jim Finke; Alberto J Montero
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

2.  The ins and outs of osteopontin.

Authors:  Claudia Chiodoni; Sabina Sangaletti; Claudio Tripodo; Mario P Colombo
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

3.  The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.

Authors:  Paul T Thevenot; Rosa A Sierra; Patrick L Raber; Amir A Al-Khami; Jimena Trillo-Tinoco; Parisa Zarreii; Augusto C Ochoa; Yan Cui; Luis Del Valle; Paulo C Rodriguez
Journal:  Immunity       Date:  2014-09-18       Impact factor: 31.745

4.  Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.

Authors:  Jessica M Haverkamp; Amber M Smith; Ricardo Weinlich; Christopher P Dillon; Joseph E Qualls; Geoffrey Neale; Brian Koss; Young Kim; Vincenzo Bronte; Marco J Herold; Douglas R Green; Joseph T Opferman; Peter J Murray
Journal:  Immunity       Date:  2014-12-11       Impact factor: 31.745

5.  Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis.

Authors:  Chong Wu; Huiheng Ning; Mingyu Liu; Jie Lin; Shufeng Luo; Wenjie Zhu; Jing Xu; Wen-Chao Wu; Jing Liang; Chun-Kui Shao; Jiaqi Ren; Bin Wei; Jun Cui; Min-Shan Chen; Limin Zheng
Journal:  J Clin Invest       Date:  2018-07-09       Impact factor: 14.808

6.  Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia.

Authors:  Alex G Cuenca; Angela L Cuenca; Robert D Winfield; Dallas N Joiner; Lori Gentile; Matthew J Delano; Kindra M Kelly-Scumpia; Philip O Scumpia; Michael K Matheny; Philip J Scarpace; Lizette Vila; Philip A Efron; Drake M LaFace; Lyle L Moldawer
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

7.  Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer.

Authors:  Rosa A Sierra; Paul Thevenot; Patrick L Raber; Yan Cui; Chris Parsons; Augusto C Ochoa; Jimena Trillo-Tinoco; Luis Del Valle; Paulo C Rodriguez
Journal:  Cancer Immunol Res       Date:  2014-05-15       Impact factor: 11.151

Review 8.  Complexity and challenges in defining myeloid-derived suppressor cells.

Authors:  Vera Damuzzo; Laura Pinton; Giacomo Desantis; Samantha Solito; Ilaria Marigo; Vincenzo Bronte; Susanna Mandruzzato
Journal:  Cytometry B Clin Cytom       Date:  2014-12-12       Impact factor: 3.058

9.  Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice.

Authors:  Parvin Forghani; Wayne Harris; Cynthia R Giver; Abbas Mirshafiey; Jacques Galipeau; Edmund K Waller
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

10.  Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer.

Authors:  Parvin Forghani; Mohammad R Khorramizadeh; Edmund K Waller
Journal:  Cancer Med       Date:  2014-01-20       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.